Racura Oncology Ltd (ASX:RAC)

Market Cap	529.90M
Revenue (ttm)	6.04M
Net Income (ttm)	-4.79M
Shares Out	180.85M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	196,918
Average Volume	140,756
Open	2.930
Previous Close	2.930
Day's Range	2.860 - 3.040
52-Week Range	0.920 - 4.900
Beta	1.17
RSI	55.46
Earnings Date	Feb 24, 2026

About Racura Oncology

Racura Oncology Ltd operates as a clinical biopharmaceutical company focuses on the cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that functions through G4-DNA and RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-small ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RAC

Financial Performance

In 2025, Racura Oncology's revenue was 6.04 million, an increase of 24.96% compared to the previous year's 4.84 million. Losses were -4.79 million, -65.36% less than in 2024.